Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Rande Is . . . HOME -- Ignore unavailable to you. Want to Upgrade?

To: Rande Is who wrote (13004)	9/30/1999 5:00:00 PM
From: Bob	Read Replies (1) \| Respond to of 57584

Rande: one of our old SAM's SGDE & AMZN biz.yahoo.com

To: Rande Is who wrote (13004)	9/30/1999 5:49:00 PM
From: OpusX	Read Replies (1) \| Respond to of 57584

CVTX Rande, I know that you have not been following biotechs on this thread too much but I was wondering if you or anyone else has thoughts on this co. and an upcoming seconday. I bought the stock because they are developing a new class of drug for "angina" it changes the primary biochemical pathway that the heart uses to produce energy. Normally the heart burns glucose as it's main source of fuel. The new drug enables the heart to burn fatty acids instead. This, since it uses less ATP per unit of energy puts less of a workload on the heart thereby relieving the symptoms of CHF. It is the first new class of drug to treat this disease state in something like 20 years. <<< Type of Offering: Follow-On Offering Proposed Symbol: CVTX Type of Security: Common Stock Expected Size of Offering: 4,000,000 Expected Price Range: Set at time of pricing Expected Pricing Date: 1999/10/05 Brief Description of Offering Company: CV Therapeutics is a biopharmaceutical company engaged in the discovery and development of new small molecule drugs to treat cardiovascular disease, the leading cause of death in the United States. Lead Manager: Donaldson, Lufkin & Jenrette the symptoms of CHF.>>> Would this lead to a dilution for shareholders, or could it be a good thing since it obviously would procure more funds for R&D? Thanks, Robert